A new approach to identifying “signposts” on cancer cells may help immune cells eliminate the disease
With new immunotherapy treatments for melanoma, recovery rates have risen dramatically, in some cases to around 50%. But they could be much higher: A new study led by researchers at the Weizmann Institute of Science showed, in lab dishes and animal studies, that a highly personalized approach could help the immune cells improve their abilities to recognize the cancer and kill it. The results of this study were published today in Cancer Discovery.
Today’s immunotherapies involve administering antibodies to unlock the natural immune T cells that recognize and kill cancer cells; or else growing and reactivating these T cells outside the body and returning them in a ‘weaponized’ form. “But none of this will kill the cancer if the immune cells do not recognize the ‘signposts’ that mark cancer cells as foreign,” says Prof. Yardena Samuels of the Institute’s Molecular Cell Biology Department.
Groups around the world are searching for such signposts – mutated peptides known as neo-antigens on the cancer cells’ outer membranes. Identifying the particular peptides that present themselves to the T cell can then help develop personalized cancer vaccines based on neo-antigen profiles. One of the problems in uncovering neo-antigens in cancers like melanoma, however, is that they are presented by a protein complex called HLA – a complex that can come in thousands of versions, even without the addition of cancerous mutations. Indeed, the algorithms that are often used to search the cancer-cell genome for possible neo-antigens had predicted hundreds of possible candidates.
Fewer neo-antigens, better results
Samuels, together with her PhD student Shelly Kalaora and in collaboration with Prof Arie Admon of the Technion – Israel Institute of Technology, bypassed the algorithm methods. They used a method Admon had developed to remove the peptides from the melanoma cells’ HLA complex and investigate their interactions with T cells. Says Samuels: “We discovered that tumors present many fewer neo-antigens than we expected. Our neo-antigen and corresponding T-cell-identification strategies were so robust, our neo-antigen-specific T cells killed 90% of their target melanoma cells both on plates and in mice. This suggests possible clinical applications for the near future. Some of the peptides we identified are neo-antigens that had not even shown up in the algorithm studies; in other words, the method we used, called HLA peptidomics, is really complementary to these methods.
Samuels and Kalaora worked with a team that included Dr. Eytan Ruppin of the National Cancer Institute, USA; Dr. Jennifer Wargo of the University of Texas MD Anderson Cancer Center, Houston, and Prof. Nir Friedman of the Weizmann Institute of Science’s Molecular Cell Biology Department.
Neo-antigen-specific T cells killed 90% of their target melanoma cells
For some of the patients the group had obtained multiple samples, and this enabled them to ask questions about metastasis – for example, whether the same neo-antigens were present on secondary tumors after the cancer had spread to other organs. “This is the first time that HLA peptide studies of multiple metastases derived from the same patient have ever been performed. The significant similarity between the various HLA-peptidomes has strong implications for the process of choosing neo-antigens for patient treatment, showing that it is clearly essential not only to identify the immunogenic peptides presented on the cancer cells, but to select the ones that are common to the patient’s metastases. This can then help direct systemic therapeutic responses in patients with multiple metastases,” says Kalaora.
A new drug for every patient
And then the group took their findings one step further: Using natural T cells extracted from 14 of the patients, the researchers identified those that most strongly react with the neo-antigens. They sequenced the genomes of these cells, grew them and tested them in animal models with the patients’ tumor cells. In both lab dish experiments and mice, they showed that the response of the T cells they identified was highly effective in fighting the cancer.
Samuels points out that “although this research is experimental right now, the findings are highly relevant to clinical research, as groups around the world have already worked out the basics of developing therapeutic anti-cancer treatments based on neo-antigens. As almost all the neo-antigens detected in patients thus far are individual – and unique to the particular cancerous tissue – they constitute an ideal class of anti-cancer targets. This would be the ultimate “personalized” cancer therapy – a new drug is created for every patient.”
The Latest on: Neo-antigens
via Google News
The Latest on: Neo-antigens
- Twist Bioscience Corporation: Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapieson November 26, 2020 at 4:00 pm
The companies will leverage Neogene's proprietary expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells due to cancer-associated DNA mutations, together with Twist's ...
- TILs, the Ultimate in Personalized Immunotherapy, Move Closer to Marketon November 24, 2020 at 6:19 am
Until now, the field of cell-based immunotherapy has been dominated by chimeric antigen receptor (CAR) T cells, with groundbreaking FDA approvals for 3 drugs across several types of hematologic ...
- Zacks Investment Research Lowers Xenetic Biosciences (NASDAQ:XBIO) to Sellon November 21, 2020 at 12:07 am
Zacks Investment Research lowered shares of Xenetic Biosciences (NASDAQ:XBIO) from a hold rating to a sell rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, ...
- Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further ...on November 20, 2020 at 1:33 am
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours - Financing includes ...
- Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Updateon November 13, 2020 at 3:11 pm
("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens ...
- Personalis' (PSNL) CEO John West on Q3 2020 Results - Earnings Call Transcripton November 8, 2020 at 3:47 am
Our technology allows us to identify biomarkers, including neoantigens across all types of cancer, providing comprehensive data from all 20,000 human genes, all from a small tissue or liquid ...
- Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 6th Annual Israel Conferenceon November 5, 2020 at 6:08 am
a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at ...
- Transgene Presents Its Individualized Immunotherapy, TG4050, at The Annual Neoantigen Based Therapies Summiton November 4, 2020 at 11:31 pm
Tax Planning Personal Finance Save for College Save for Retirement Invest in Retirement Research Mutual Funds Stocks ETFs Bonds Best Investments ...
- Transgene Presents Its Individualized Immunotherapy, TG4050, at The Annual Neoantigen Based Therapies Summiton November 4, 2020 at 10:46 pm
TG4050 is an individualized cancer vaccine based on our myvac® technology that has the ability to elicit an immune response against up to 30 patient-specific tumor neoantigens. Our partnership ...
via Bing News